What triggered fresh interest in Xeris Biopharma Holdings (XERS)?

Xeris Biopharma Holdings (XERS) has drawn fresh attention after reporting fourth quarter and full year 2025 results that moved from loss to profit, paired with new 2026 revenue guidance and a US$40.7 million shelf registration filing.

Despite Xeris Biopharma Holdings posting improved earnings and setting 2026 revenue guidance, recent share price returns have been weak, with a 1 month share price return of a 17.12% decline and a year to date share price return of a 20.95% decline, contrasting with a 1 year total shareholder return of 37.03% and a very large 3 year total shareholder return.

If this earnings story has you thinking about what else might be on the move in healthcare, it could be a good moment to scan 32 healthcare AI stocks as potential next ideas.

With Xeris now reporting profit, setting 2026 revenue guidance of US$375 million to US$390 million, and trading at a large discount to analyst price targets, is this a genuine buying opportunity or is the market already pricing in future growth?

Most Popular Narrative: 47.9% Undervalued

With Xeris Biopharma Holdings last closing at $5.81 against a most followed fair value estimate of $11.14, the narrative points to a wide valuation gap built on ambitious growth and margin assumptions that investors may want to understand in detail.

Persistent high gross margins, alongside scaling sales of Gvoke, Recorlev, and Keveyis, set the stage for operational leverage and sustainable EBITDA and net margin improvements as revenue expands and expense ratios decline over time.

Curious what kind of revenue climb and margin reset sit behind that fair value, and how they tie into future earnings power and valuation multiples? The narrative emphasizes compounding top line growth, improving profitability, and a richer earnings profile than today, while the exact mix of those assumptions may be less obvious.

Result: Fair Value of $11.14 (UNDERVALUED)

However, that upbeat story could crack if the narrow product lineup underperforms or if rising R&D and SG&A expenses outpace the revenue path analysts are assuming.

Another angle on valuation: what does the P/S ratio say?

While the narrative leans on ambitious growth and margin forecasts, the current P/S ratio of 3.4x paints a more mixed picture. It sits below the US Pharmaceuticals average of 3.9x and it is also below Xeris Biopharma Holdings' own fair ratio estimate of 5.9x. This points to potential upside but also raises questions about execution risk and whether the market will ever price in that gap.

Next Steps

If this mix of optimism and caution has you thinking hard about Xeris, it is worth checking the numbers yourself and moving quickly to form your own stance, especially with 3 key rewards and 2 important warning signs highlighting what the market currently sees on both sides of the story.

Looking for more investment ideas?

Before you move on, consider building a broader watchlist by including a few different types of opportunities that could complement or contrast with Xeris.

• Scan our list of 32 elite penny stocks with strong financials to look for potential bargains that combine lower share prices with stronger fundamentals than you might expect.
• Review the 49 high quality undervalued stocks to concentrate on companies that appear to be trading below their estimated worth.
• Explore the 63 resilient stocks with low risk scores to prioritize companies with relatively lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.